In pivotal phase II studies, anti‐CD19 CAR T‐cell therapy demonstrated promising efficacy for rel/ref DLBCL after initial treatment23 or the last line of treatment22 (ORR: 86% and 40%, respectively). The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.